Background and Aims:As a subunit of the condensin complex,NCAPG has an important role in maintaining chromosome condensation,but its biological function and regulatory mechanism in hepatocellular carcinoma(HCC)remains...Background and Aims:As a subunit of the condensin complex,NCAPG has an important role in maintaining chromosome condensation,but its biological function and regulatory mechanism in hepatocellular carcinoma(HCC)remains undefined.Methods:The prognostic ability of NCAPG in HCC patients was examined by univariate and multivariate Cox regression analysis.ROC curves were plotted to compare the predictive ability of NCAPG and AFP.Double luciferase reporter system,and ChIP were used to investigate transcriptional potential of E2F1 to NCAPG.Pyroptosis was observed by scanning electron microscopy.Protein expression of NCAPG,E2F1,and major proteins constituting NLRP3 inflammasome was determined by western blotting and ELISA.An in vivo tumor formation assay was conducted to verify the in vitro results.Results:Up-regulated NCAPG was identified in HCC tissues compared with adjacent tissue and high NCAPG was positively correlated with poor prognosis.Serum NCAPG mRNA level was a prognostic factor in HCC patients and also a diagnostic factor with higher predictive ability compared with AFP[AUROC 0.766(95%CI:0.650–0.881)vs.0.649(95%CI 0.506–0.793)].HBx transfection resulted in concomitant up-regulation of E2F1 and NCAPG.E2F1 significantly increased the activity of luciferase reporter fused with NCAPG reporter,and the interaction of E2F1 and NCAPG gene was confirmed by ChIP.Silencing of E2F1 resulted in significant down-regulation of NCAPG.Knockdown of NCAPG promote pyroptosis mediated by NLRP3 inflammasome activation in multiple HCC cell lines and also suppressed tumorigenesis in vitro.Conclusions:We identified a novel role of NCAPG in the regulation of NLRP3 inflammasome-mediated pyroptosis,which was regulated by its upstream transactivator,E2F1.The role of E2F1-NCAPG-NLRP3 regulation of pyroptosis network may be a potential target in HCC treatment.展开更多
The liver is the largest glandular organ in the body and has a unique distribution of cells and biomolecules.However,the treatment outcome of end-stage liver disease is extremely poor.Single-cell sequencing is a new a...The liver is the largest glandular organ in the body and has a unique distribution of cells and biomolecules.However,the treatment outcome of end-stage liver disease is extremely poor.Single-cell sequencing is a new advanced and powerful technique for identifying rare cell populations and biomolecules by analyzing the characteristics of gene expression between individual cells.These cells and biomolecules might be used as potential targets for immunotherapy of liver diseases and contribute to the development of precise individualized treatment.Compared to whole-tissue RNA sequencing,single-cell RNA sequencing(scRNA-seq)or other single-cell histological techniques have solved the problem of cell population heterogeneity and characterize molecular changes associated with liver diseases with higher accuracy and resolution.In this review,we comprehensively summarized single-cell approaches including transcriptomic,spatial transcriptomic,immunomic,proteomic,epigenomic,and multiomic technologies,and described their application in liver physiology and pathology.We also discussed advanced techniques and recent studies in the field of single-cell;our review might provide new insights into the pathophysiological mechanisms of the liver to achieve precise and individualized treatment of liver diseases.展开更多
Background China bears a high burden of both hepatitis B virus(HBV)infection and type 2 diabetes mellitus(T2DM).T2DM accelerates the progression of liver disease among individuals infected with HBV.This study aims to ...Background China bears a high burden of both hepatitis B virus(HBV)infection and type 2 diabetes mellitus(T2DM).T2DM accelerates the progression of liver disease among individuals infected with HBV.This study aims to assess the excess disease burden caused by comorbid T2DM among HBV-infected individuals in China.Methods We estimated the disease burden of HBV and its complications in China from 2006 to 2030 using individual-based Markov models.The baseline population consisted of 93 million HBV-infected individuals derived from the 2006 National Serological Epidemiological Survey.We developed two models:one incorporated the impact of T2DM on the disease progression of HBV infection,while the other did not consider the impact of T2DM.By com-paring the outcomes between these two models,we estimated the excess disease burden attributable to comorbid T2DM among HBV-infected individuals.Results The incidence of severe HBV complications,including cirrhosis,hepatocellular carcinoma(HCC),and liver-related deaths,exhibited an increasing trend from 2006 to 2030 among the Chinese HBV-infected population.Comor-bid T2DM increased the annual incidence and cumulative cases of severe HBV complications.From 2006 to 2022,comorbid T2DM caused 791,000(11.41%),244,000(9.27%),377,000(8.78%),and 796,000(12.19%)excess cases of compensated cirrhosis,decompensated cirrhosis,HCC,and liver-related deaths,respectively.From 2023 to 2030,comorbid T2DM is projected to result in an 8.69%excess in severe HBV complications and an 8.95%increase in liver-related deaths.Among individuals aged 60 and older at baseline,comorbid T2DM led to a 21.68%excess in severe HBV complications and a 28.70%increase in liver-related deaths from 2006 to 2022,with projections indicating a fur-ther 20.76%increase in severe HBV complications and an 18.31%rise in liver-related deaths over the next seven years.Conclusions Comorbid T2DM imposes a substantial disease burden on individuals with HBV infection in China.Healthcare providers and health policymakers should develop and implement tailored strategies for the effective management and control of T2DM in individuals with HBV infection.展开更多
B cell response plays a critical role against SARS-CoV-2 infection.However,little is known about the diversity and frequency of the paired SARS-CoV-2 antigen-specific BCR repertoire after SARS-CoV-2 infection.Here,we ...B cell response plays a critical role against SARS-CoV-2 infection.However,little is known about the diversity and frequency of the paired SARS-CoV-2 antigen-specific BCR repertoire after SARS-CoV-2 infection.Here,we performed single-cell RNA sequencing and VDJ sequencing using the memory and plasma B cells isolated from five convalescent COVID-19 patients,and analyzed the spectrum and transcriptional heterogeneity of antibody immune responses.Via linking BCR to antigen specificity through sequencing(LIBRA-seq),we identified a distinct activated memory B cell subgroup(CD11c^(high) CD95^(high))had a higher proportion of SARS-CoV-2 antigen-labeled cells compared with memory B cells.Our results revealed the diversity of paired BCR repertoire and the non-stochastic pairing of SARS-CoV-2 antigen-specific immunoglobulin heavy and light chains after SARS-CoV-2 infection.The public antibody clonotypes were shared by distinct convalescent individuals.Moreover,several antibodies isolated by LIBRA-seq showed high binding affinity against SARS-CoV-2 receptor-binding domain(RBD)or nucleoprotein(NP)via ELISA assay.Two RBD-reactive antibodies C14646P3S and C2767P3S isolated by LIBRA-seq exhibited high neutralizing activities against both pseudotyped and authentic SARS-CoV-2 viruses in vitro.Our study provides fundamental insights into B cell response following SARS-CoV-2 infection at the single-cell level.展开更多
Background and Aims:Long non-coding RNA small nucleolar RNA host genes(SNHGs)play a critical role in the occurrence and development of tumors.In this study,we aimed to investigate the role of SNHG4 in hepatocellular c...Background and Aims:Long non-coding RNA small nucleolar RNA host genes(SNHGs)play a critical role in the occurrence and development of tumors.In this study,we aimed to investigate the role of SNHG4 in hepatocellular carcinoma(HCC)and its underlining mechanism.Methods:Datasets were acquired from The Cancer Genome Atlas(TCGA)database.lncLocator 2.0 was used to identify the distribution of SNHG4 in HCC cells.Gene expression,Kaplan-Meier survival,microRNA and transcription factor target analyses were performed with the University of Alabama Cancer(UALCAN)Database,Kaplan-Meier Plotter,LinkedOmics,WebGestalt and gene set enrichment analysis,respectively.Gene Ontology and pathway enrichment analyses and assessment of RNA binding proteins were performed by R software,circlncRNAnet and Encyclopedia of RNA Interactomes(EN-CORI).In addition,CirclncRNAnet and ENCORI were used to find the correlation between SNHG4 and important proteins,while the prognostic value was assessed with the Human Protein Atlas database and Kaplan-Meier Plotter.Results:Expression of SNHG4 in HCC is higher in HCC tissue than in normal healthy liver tissues and is mainly distributed in the nucleus.SNHG4 positively correlated with poor prognosis(p<0.01 for overall survival and recurrence-free survival).Functional enrichment analysis revealed SNHG4 involve-ment with regulation of ribosomal RNA synthesis and the RNA processing and surveillance pathway.SNHG4 is closely associated with miR-154 and miR-206,transcription factor target E2F family and the signaling pathway for MAPK/ERK and mTOR.U2 auxiliary factor 2(U2AF2)showed strong correlation with SNHG4,while low-expression of U2AF2 showed good prognosis.Conclusions:Based on our find-ings,we infer SNHG4 may play a role in the formation of HCC via regulation of tumor-related pathways.展开更多
Background and aims:There is currently no single model for predicting Wilson's disease(WD).We aimed to create a nomogram using daily clinical parameters to improve the accuracy of WD diagnosis in patients with abn...Background and aims:There is currently no single model for predicting Wilson's disease(WD).We aimed to create a nomogram using daily clinical parameters to improve the accuracy of WD diagnosis in patients with abnormal liver function.Methods:Between July 2016 and December 2020,we identified 90 WD patients with abnormal liver function who had homozygous or compound heterozygous mutations in the ATP7B gene.The control group included 128 patients with similar liver function but no WD during the same time period.To create a nomogram,we screened potential predictive variables using the least absolute shrinkage and selection operator model and multivariate logistic regression.Results:We developed a nomogram for screening for WD based on six predictive factors:serum copper,direct bilirubin,uric acid,cholinesterase,prealbumin,and reticulocyte percentage.In the training cohort,the area under curve(AUC)of the nomogram reached 0.967(95%confidence interval(CI)0.946e0.988),while the area under the precision-recall curve was 0.961.Based on the optimal cutpoint of 213.55,our nomogram performed well,with a sensitivity of 96%and a specificity of 87%.In the validation cohort,the AUC of the nomogram was as high as 0.991(95%CI 0.970e1.000).Conclusions:We developed a nomogram that can predict the risk of WD prior to the detection of serum ceruloplasmin or urinary copper,greatly increasing screening efficiency for patients with abnormal liver function.展开更多
Background and aim:Real-world data on the effectiveness and safety of treatment with the direct-acting antiviral agent-based regimen are limited on the Chinese mainland.The aim of this study was to conduct a multicent...Background and aim:Real-world data on the effectiveness and safety of treatment with the direct-acting antiviral agent-based regimen are limited on the Chinese mainland.The aim of this study was to conduct a multicenter,prospective,real-world study of ombitasvir/paritaprevir/ritonavir(OBT/PTV/r)combined with dasabuvir(DSV)in hepatitis C virus(HCV)genotype 1b-infected non-cirrhotic or compensated cirrhotic Chinese adult patients.Materials and methods:Genotype 1b-infected patients were enrolled at eight sites in China.Patients received 25/150/100 mg of OBT/PTV/r once daily combined with 250 mg of DSV twice daily for 8 weeks or 12 weeks.Sustained virological response at 12 weeks post-treatment(SVR12)and the incidence of adverse events were assessed.We have also evaluated the effect of intensive questioning of patients who were overdue for SVR12 testing.Intention-to-treat(ITT)and modified ITT(mITT)populations were used in the analysis.Results:One hundred forty patients were included,among whom 90.0%(126/140)were newly diagnosed,9.3%(13/140)had compensated cirrhosis,92.9%(130/140)received 12 weeks of treatment,and 7.1%(10/140)received 8 weeks of treatment.In the mITT population,the virological response rate at week 4 was 96.4%(108/112),and at the end of treatment was 100%(102/102).Among these patients,139 patients completed 12 weeks of treatment,and 73 patients were followed-up.All followed-up patients achieved SVR12.There was no adverse event-related discontinuation.Serious adverse events during treatment were reported in two(1.4%)patients,and none were considered to be drug-related.Sixty-six(47.1%)patients did not return to receive the HCV RNA test at 12 weeks post-treatment.Conclusions:The rate of SVR12 was consistent with Phase III clinical studies.OBT/PTV/r combined with DSV showed effectiveness in Chinese adult patients,and both tolerability and safety profile were favorable.However,patient compliance should be further improved in the real world.展开更多
基金supported by the Natural Science Foundation of China(81870449,81670601,81370555,82100693,82170674,81902886,U22A20276)Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme(GDUPS,2017)+4 种基金the Science and Technology Program of Guangzhou,China(201903010039,2019B020228001,202206010072,202102020310,202102010155)International cooperation project of Guangdong science and technology plan(2019B020228001,2020A0505100034)Guangdong Basic and Applied Basic Research Foundation(2022A 1515110316,2020A1515110687)Natural Science Foundation of Guangdong Province,(2022A1515012453)Medical Scientific Research Foundation of Guangdong Province,China,(A2020120)Sun Yat-sen University Clinical Research 5010 Program(2016009).
文摘Background and Aims:As a subunit of the condensin complex,NCAPG has an important role in maintaining chromosome condensation,but its biological function and regulatory mechanism in hepatocellular carcinoma(HCC)remains undefined.Methods:The prognostic ability of NCAPG in HCC patients was examined by univariate and multivariate Cox regression analysis.ROC curves were plotted to compare the predictive ability of NCAPG and AFP.Double luciferase reporter system,and ChIP were used to investigate transcriptional potential of E2F1 to NCAPG.Pyroptosis was observed by scanning electron microscopy.Protein expression of NCAPG,E2F1,and major proteins constituting NLRP3 inflammasome was determined by western blotting and ELISA.An in vivo tumor formation assay was conducted to verify the in vitro results.Results:Up-regulated NCAPG was identified in HCC tissues compared with adjacent tissue and high NCAPG was positively correlated with poor prognosis.Serum NCAPG mRNA level was a prognostic factor in HCC patients and also a diagnostic factor with higher predictive ability compared with AFP[AUROC 0.766(95%CI:0.650–0.881)vs.0.649(95%CI 0.506–0.793)].HBx transfection resulted in concomitant up-regulation of E2F1 and NCAPG.E2F1 significantly increased the activity of luciferase reporter fused with NCAPG reporter,and the interaction of E2F1 and NCAPG gene was confirmed by ChIP.Silencing of E2F1 resulted in significant down-regulation of NCAPG.Knockdown of NCAPG promote pyroptosis mediated by NLRP3 inflammasome activation in multiple HCC cell lines and also suppressed tumorigenesis in vitro.Conclusions:We identified a novel role of NCAPG in the regulation of NLRP3 inflammasome-mediated pyroptosis,which was regulated by its upstream transactivator,E2F1.The role of E2F1-NCAPG-NLRP3 regulation of pyroptosis network may be a potential target in HCC treatment.
基金supported in part by the National Natural Science Foundation of China(32000892)the Guangdong Basic and Applied Basic Research Foundation(2023A1515010143)Science and Technology Program of Guangzhou,China(202102010155).
文摘The liver is the largest glandular organ in the body and has a unique distribution of cells and biomolecules.However,the treatment outcome of end-stage liver disease is extremely poor.Single-cell sequencing is a new advanced and powerful technique for identifying rare cell populations and biomolecules by analyzing the characteristics of gene expression between individual cells.These cells and biomolecules might be used as potential targets for immunotherapy of liver diseases and contribute to the development of precise individualized treatment.Compared to whole-tissue RNA sequencing,single-cell RNA sequencing(scRNA-seq)or other single-cell histological techniques have solved the problem of cell population heterogeneity and characterize molecular changes associated with liver diseases with higher accuracy and resolution.In this review,we comprehensively summarized single-cell approaches including transcriptomic,spatial transcriptomic,immunomic,proteomic,epigenomic,and multiomic technologies,and described their application in liver physiology and pathology.We also discussed advanced techniques and recent studies in the field of single-cell;our review might provide new insights into the pathophysiological mechanisms of the liver to achieve precise and individualized treatment of liver diseases.
基金National Natural Science Foundation of China(Grant No.71774178)Science and Technology Planning Project of Guangdong(Grant No.2017A020212006)National Science and Technology Major Project of the Ministry of Science and Technology of China(Grant No.2018ZX10715004).
文摘Background China bears a high burden of both hepatitis B virus(HBV)infection and type 2 diabetes mellitus(T2DM).T2DM accelerates the progression of liver disease among individuals infected with HBV.This study aims to assess the excess disease burden caused by comorbid T2DM among HBV-infected individuals in China.Methods We estimated the disease burden of HBV and its complications in China from 2006 to 2030 using individual-based Markov models.The baseline population consisted of 93 million HBV-infected individuals derived from the 2006 National Serological Epidemiological Survey.We developed two models:one incorporated the impact of T2DM on the disease progression of HBV infection,while the other did not consider the impact of T2DM.By com-paring the outcomes between these two models,we estimated the excess disease burden attributable to comorbid T2DM among HBV-infected individuals.Results The incidence of severe HBV complications,including cirrhosis,hepatocellular carcinoma(HCC),and liver-related deaths,exhibited an increasing trend from 2006 to 2030 among the Chinese HBV-infected population.Comor-bid T2DM increased the annual incidence and cumulative cases of severe HBV complications.From 2006 to 2022,comorbid T2DM caused 791,000(11.41%),244,000(9.27%),377,000(8.78%),and 796,000(12.19%)excess cases of compensated cirrhosis,decompensated cirrhosis,HCC,and liver-related deaths,respectively.From 2023 to 2030,comorbid T2DM is projected to result in an 8.69%excess in severe HBV complications and an 8.95%increase in liver-related deaths.Among individuals aged 60 and older at baseline,comorbid T2DM led to a 21.68%excess in severe HBV complications and a 28.70%increase in liver-related deaths from 2006 to 2022,with projections indicating a fur-ther 20.76%increase in severe HBV complications and an 18.31%rise in liver-related deaths over the next seven years.Conclusions Comorbid T2DM imposes a substantial disease burden on individuals with HBV infection in China.Healthcare providers and health policymakers should develop and implement tailored strategies for the effective management and control of T2DM in individuals with HBV infection.
基金supported by National Natural Science Foundation of China(31970881)and(82041046)to Y.Q.C.Shenzhen Science and Technology Program under Grant(JCYJ20190807154603596 and JCYJ20200109142438111)+2 种基金the National Key Research and Development Project(2020YFC0841700)to M.W.the National Natural Science Foundation of China(32041002)to D.Y.G.the Special Fund for COVID-19 Epidemic Prevention&Control of Zhuhai City of China granted to S.D.C.
文摘B cell response plays a critical role against SARS-CoV-2 infection.However,little is known about the diversity and frequency of the paired SARS-CoV-2 antigen-specific BCR repertoire after SARS-CoV-2 infection.Here,we performed single-cell RNA sequencing and VDJ sequencing using the memory and plasma B cells isolated from five convalescent COVID-19 patients,and analyzed the spectrum and transcriptional heterogeneity of antibody immune responses.Via linking BCR to antigen specificity through sequencing(LIBRA-seq),we identified a distinct activated memory B cell subgroup(CD11c^(high) CD95^(high))had a higher proportion of SARS-CoV-2 antigen-labeled cells compared with memory B cells.Our results revealed the diversity of paired BCR repertoire and the non-stochastic pairing of SARS-CoV-2 antigen-specific immunoglobulin heavy and light chains after SARS-CoV-2 infection.The public antibody clonotypes were shared by distinct convalescent individuals.Moreover,several antibodies isolated by LIBRA-seq showed high binding affinity against SARS-CoV-2 receptor-binding domain(RBD)or nucleoprotein(NP)via ELISA assay.Two RBD-reactive antibodies C14646P3S and C2767P3S isolated by LIBRA-seq exhibited high neutralizing activities against both pseudotyped and authentic SARS-CoV-2 viruses in vitro.Our study provides fundamental insights into B cell response following SARS-CoV-2 infection at the single-cell level.
基金supported by grants from the National key research and development program(2018YFC1315400)the National Natural Science Foundation of China(Nos.81773176,81870449).
文摘Background and Aims:Long non-coding RNA small nucleolar RNA host genes(SNHGs)play a critical role in the occurrence and development of tumors.In this study,we aimed to investigate the role of SNHG4 in hepatocellular carcinoma(HCC)and its underlining mechanism.Methods:Datasets were acquired from The Cancer Genome Atlas(TCGA)database.lncLocator 2.0 was used to identify the distribution of SNHG4 in HCC cells.Gene expression,Kaplan-Meier survival,microRNA and transcription factor target analyses were performed with the University of Alabama Cancer(UALCAN)Database,Kaplan-Meier Plotter,LinkedOmics,WebGestalt and gene set enrichment analysis,respectively.Gene Ontology and pathway enrichment analyses and assessment of RNA binding proteins were performed by R software,circlncRNAnet and Encyclopedia of RNA Interactomes(EN-CORI).In addition,CirclncRNAnet and ENCORI were used to find the correlation between SNHG4 and important proteins,while the prognostic value was assessed with the Human Protein Atlas database and Kaplan-Meier Plotter.Results:Expression of SNHG4 in HCC is higher in HCC tissue than in normal healthy liver tissues and is mainly distributed in the nucleus.SNHG4 positively correlated with poor prognosis(p<0.01 for overall survival and recurrence-free survival).Functional enrichment analysis revealed SNHG4 involve-ment with regulation of ribosomal RNA synthesis and the RNA processing and surveillance pathway.SNHG4 is closely associated with miR-154 and miR-206,transcription factor target E2F family and the signaling pathway for MAPK/ERK and mTOR.U2 auxiliary factor 2(U2AF2)showed strong correlation with SNHG4,while low-expression of U2AF2 showed good prognosis.Conclusions:Based on our find-ings,we infer SNHG4 may play a role in the formation of HCC via regulation of tumor-related pathways.
基金supported by the Science and Technology Planning Project of Guangdong Province,China(2019B020228001)National Key R&D Program of China(2018YFC1315400)5010 Project of Sun Yat-sen University(No.2018024).
文摘Background and aims:There is currently no single model for predicting Wilson's disease(WD).We aimed to create a nomogram using daily clinical parameters to improve the accuracy of WD diagnosis in patients with abnormal liver function.Methods:Between July 2016 and December 2020,we identified 90 WD patients with abnormal liver function who had homozygous or compound heterozygous mutations in the ATP7B gene.The control group included 128 patients with similar liver function but no WD during the same time period.To create a nomogram,we screened potential predictive variables using the least absolute shrinkage and selection operator model and multivariate logistic regression.Results:We developed a nomogram for screening for WD based on six predictive factors:serum copper,direct bilirubin,uric acid,cholinesterase,prealbumin,and reticulocyte percentage.In the training cohort,the area under curve(AUC)of the nomogram reached 0.967(95%confidence interval(CI)0.946e0.988),while the area under the precision-recall curve was 0.961.Based on the optimal cutpoint of 213.55,our nomogram performed well,with a sensitivity of 96%and a specificity of 87%.In the validation cohort,the AUC of the nomogram was as high as 0.991(95%CI 0.970e1.000).Conclusions:We developed a nomogram that can predict the risk of WD prior to the detection of serum ceruloplasmin or urinary copper,greatly increasing screening efficiency for patients with abnormal liver function.
基金This work was supported by a grant for clinical investigation from Key Projects of Guangdong Science and Technology Plan of China(2014B020212025).
文摘Background and aim:Real-world data on the effectiveness and safety of treatment with the direct-acting antiviral agent-based regimen are limited on the Chinese mainland.The aim of this study was to conduct a multicenter,prospective,real-world study of ombitasvir/paritaprevir/ritonavir(OBT/PTV/r)combined with dasabuvir(DSV)in hepatitis C virus(HCV)genotype 1b-infected non-cirrhotic or compensated cirrhotic Chinese adult patients.Materials and methods:Genotype 1b-infected patients were enrolled at eight sites in China.Patients received 25/150/100 mg of OBT/PTV/r once daily combined with 250 mg of DSV twice daily for 8 weeks or 12 weeks.Sustained virological response at 12 weeks post-treatment(SVR12)and the incidence of adverse events were assessed.We have also evaluated the effect of intensive questioning of patients who were overdue for SVR12 testing.Intention-to-treat(ITT)and modified ITT(mITT)populations were used in the analysis.Results:One hundred forty patients were included,among whom 90.0%(126/140)were newly diagnosed,9.3%(13/140)had compensated cirrhosis,92.9%(130/140)received 12 weeks of treatment,and 7.1%(10/140)received 8 weeks of treatment.In the mITT population,the virological response rate at week 4 was 96.4%(108/112),and at the end of treatment was 100%(102/102).Among these patients,139 patients completed 12 weeks of treatment,and 73 patients were followed-up.All followed-up patients achieved SVR12.There was no adverse event-related discontinuation.Serious adverse events during treatment were reported in two(1.4%)patients,and none were considered to be drug-related.Sixty-six(47.1%)patients did not return to receive the HCV RNA test at 12 weeks post-treatment.Conclusions:The rate of SVR12 was consistent with Phase III clinical studies.OBT/PTV/r combined with DSV showed effectiveness in Chinese adult patients,and both tolerability and safety profile were favorable.However,patient compliance should be further improved in the real world.
